Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped
Roche's Genentech subsidiary is developing a pill-based diabetes and weight loss drug called CT-996. The new GLP-1 drug is in phase 1 clinical trials and saw patients losing 7% of their weight in four weeks.
Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise
A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Novo Nordisk (NVO) lower Wednesday.
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
Does Roche have weight-loss giants Novo Nordisk and Eli Lilly on the run?
The potential of a once-a-day pill for obesity unsettled the weight loss stocks. Shares in Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) were off 4% and 2% respectively on news that Roche's new pill had shown promise in early-stage clinical trials.
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.
Roche shares jump on drugmaker's early-stage data on weight-loss drug
Shares of Swiss drugmaker Roche rallied on Wednesday after the company's early-stage trial of an oral weight-loss drug showed it had promise.
Roche Climbs As Once-Daily Weight Loss Pill Shows Promise
Shares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk and Eli Lilly in the burgeoning diabetes and obesity drug market amid growing evidence the drugs can treat many other health conditions like kidney disease and sleep apnea.
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks.
Roche reports positive early results in CT-966 obesity drug trial
Roche said on Wednesday that its CT-996, a GLP-1 receptor agonist to treat obesity and type 2 diabetes, has had positive results in phase one of its clinical trial.
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
Roche reintroduces recalled eye implant in US
Genentech, a unit of Roche Group , said on Monday it has reintroduced its ocular implant, Susvimo, in the United States, following the end of a voluntary recall.
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.
